Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $4.2 million.

  • Gain Therapeutics' Total Current Liabilities fell 923.2% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 923.2%. This contributed to the annual value of $3.9 million for FY2024, which is 2098.28% down from last year.
  • Gain Therapeutics' Total Current Liabilities amounted to $4.2 million in Q3 2025, which was down 923.2% from $5.2 million recorded in Q2 2025.
  • Gain Therapeutics' Total Current Liabilities' 5-year high stood at $6.5 million during Q2 2024, with a 5-year trough of $2.3 million in Q1 2021.
  • In the last 5 years, Gain Therapeutics' Total Current Liabilities had a median value of $4.3 million in 2022 and averaged $4.4 million.
  • As far as peak fluctuations go, Gain Therapeutics' Total Current Liabilities skyrocketed by 8124.0% in 2022, and later plummeted by 2098.28% in 2024.
  • Over the past 5 years, Gain Therapeutics' Total Current Liabilities (Quarter) stood at $2.6 million in 2021, then skyrocketed by 61.61% to $4.1 million in 2022, then rose by 19.99% to $4.9 million in 2023, then decreased by 20.98% to $3.9 million in 2024, then grew by 6.63% to $4.2 million in 2025.
  • Its Total Current Liabilities stands at $4.2 million for Q3 2025, versus $5.2 million for Q2 2025 and $5.0 million for Q1 2025.